Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PIM Kinase Inhibitor AZD1208 for Treatment of MYC-Driven Prostate Cancer

13 Dec 2014

Abstract excerpt

BACKGROUND: PIM1 kinase is coexpressed with c-MYC in human prostate cancers (PCs) and dramatically enhances c-MYC-induced tumorigenicity. Here we examine the effects of a novel oral PIM inhibitor, AZD1208, on prostate tumorigenesis and recurrence. METHODS: A mouse c-MYC/Pim1-transduced tissue recombination PC model, Myc-CaP allografts, and human PC xenografts were treated with AZD1208 (n = 5-11 per group)....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to Mechanisms of cancer metastasis
Share to Melanoma and MAPK Pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25505253
DOI: 10.1093/jnci/dju407

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PIM Kinase Inhibitor AZD1208 for Treatment of MYC-Driven Prostate CancerPMID 25505253Read ↗

PIM1 kinase as a target in prostate cancer: roles in tumorigenesis, castration resistance, and docetaxel resistance.Semantic proximity Read ↗

Pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity.Semantic proximity Read ↗

Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes.Semantic proximity Read ↗

Multiplex profiling identifies clinically relevant signalling proteins in an isogenic prostate cancer model of radioresistanceSemantic proximity Read ↗

A kinome-wide CRISPR screen identifies CK1α as a target to overcome enzalutamide resistance of prostate cancerSemantic proximity Read ↗

Acute BRCAness induction and AR pathway blockage through CDK12/7/9 degradation enhances PARP inhibitor sensitivity in prostate cancerSemantic proximity Read ↗

A kinome-wide CRISPR screen identifies CK1α as a novel target to overcome enzalutamide resistance of prostate cancerSemantic proximity Read ↗

N-Myc promotes therapeutic resistance development of neuroendocrine prostate cancer by differentially regulating miR-421/ATM pathwaySemantic proximity Read ↗

Pim-selective inhibitor DHPCC-9 reveals Pim kinases as potent stimulators of cancer cell migration and invasionSemantic proximity Read ↗

Targeting PIM Kinases to Overcome Therapeutic Resistance in CancerSemantic proximity Read ↗

PIM1 kinase as a promise of targeted therapy in prostate cancer stem cellsSemantic proximity Read ↗

Targeting CXCR1 and CXCR2 to overcome radiotherapy resistance in PTEN-deficient prostate carcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.